Top

Published in:

01-11-2008 | Original Paper

Variants in hormone biosynthesis genes and risk of endometrial cancer

Authors: Sara H. Olson, Irene Orlow, Sharon Bayuga, Camelia Sima, Elisa V. Bandera, Katherine Pulick, Shameka Faulkner, Diana Tommasi, Daniel Egan, Pampa Roy, Homer Wilcox, Ali Asya, Ippolito Modica, Haider Asad, Robert Soslow, Ann G. Zauber

Published in: Cancer Causes & Control | Issue 9/2008

Abstract

We investigated the risk associated with variants in three genes involved in estrogen biosynthesis, CYP11A1, CYP17A1, and CYP19A1, in the population-based case–control study of Estrogen, Diet, Genetics, and Endometrial Cancer. This study was conducted in New Jersey in 2001–2006 with 417 cases and 402 controls. For CYP11A1, there was no association between the number of [TTTTA]_n repeats (D15S520) and risk. For CYP17A1, risk was somewhat lower among women with the C/C genotype at T-34C (rs743572) (adjusted OR = 0.65, 95% CI 0.41–1.02). For CYP19A1, risk was lower among women homozygous for the 3-bp deletion (rs11575899) in exon 4 (adjusted OR = 0.44, 95% CI 0.26–0.76), while the number of [TTTA]_n repeats was not significantly related to risk: the adjusted OR for n = 7/7 repeats versus n > 7/>7 repeats was 0.81 (95% CI 0.54–1.23). In stratified analyses, results for CYP19A1 were stronger among women with higher (≥27.4) body mass index: for the homozygous deletion, OR = 0.30 (95% CI 0.15–0.62); for the n = 7/7 genotype, OR = 0.49 (95% CI 0.26–0.93). The interaction between the n = 7/7 genotype and BMI was statistically significant (p = 0.01). The insertion/deletion variant in CYP19A1 appears to be related to risk of endometrial cancer; risk associated with variants in this gene may vary according to BMI.

ACS (2007) Cancer facts and figures (2007) American Cancer Society, Atlanta

Sherman ME (2000) Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13:295–308PubMedCrossRef

Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57:205–212PubMed

Hartz AJ, Barboriak PN, Wong A, Katayama KP, Rimm AA (1979) The association of obesity with infertility and related menstrual abnormalities in women. Int J Obes 3:57–73PubMed

Jain A, Polotsky AJ, Rochester D et al (2007) Pulsatile Luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab 92:2468–2473PubMedCrossRef

Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11:1531–1543PubMed

Kirschner MA, Schneider G, Ertel NH, Worton E (1982) Obesity, androgens, estrogens, and cancer risk. Cancer Res 42:3281s–3285sPubMed

MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK (1978) Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 130:448–455PubMed

Siiteri PK (1981) Extraglandular oestrogen formation and serum binding of oestradiol: relationship to cancer. J Endocrinol 89(Suppl):119P–129PPubMed

10.

Lacey JV Jr, Leitzmann MF, Chang SC et al (2007) Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Cancer 109:1303–1311PubMedCrossRef

11.

Strom BL, Schinnar R, Weber AL et al (2006) Case–control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 164:775–786PubMedCrossRef

12.

Potischman N, Hoover RN, Brinton LA et al (1996) Case–control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 88:1127–1135PubMedCrossRef

13.

Lukanova A, Lundin E, Micheli A et al (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 108:425–432PubMedCrossRef

14.

Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579–591PubMedCrossRef

15.

Healey CS, Dunning AM, Durocher F et al (2000) Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 21:189–193PubMedCrossRef

16.

Baxter SW, Choong DY, Eccles DM, Campbell IG (2001) Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 22:347–349PubMedCrossRef

17.

Ronaghi M (2003) Pyrosequencing for SNP genotyping. Methods Mol Biol 212:189–195PubMed

18.

Franchina M, Kadin ME, Abraham LJ (2005) Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders. Cancer Epidemiol Biomarkers Prev 14:1322–1325PubMedCrossRef

19.

Harrell FE (2001) Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. Springer, New York

20.

Liang KY, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13–22CrossRef

21.

Olson SH, Bandera EV, Orlow I (2007) Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am J Epidemiol 165:235–245PubMedCrossRef

22.

Johnson MM, Houck J, Chen C (2005) Screening for deleterious nonsynonymous single-nucleotide polymorphisms in genes involved in steroid hormone metabolism and response. Cancer Epidemiol Biomarkers Prev 14:1326–1329PubMedCrossRef

23.

Gaudet MM, Lacey JV Jr., Lissowska J et al (2008) Genetic variation in CYP17 and endometrial cancer risk. Hum Genet 123:155–162PubMedCrossRef

24.

Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I (2001) A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 61:3955–3960PubMed

25.

Carey AH, Waterworth D, Patel K et al (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3:1873–1876PubMedCrossRef

26.

Nedelcheva Kristensen V, Haraldsen EK, Anderson KB et al (1999) CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 59:2825–2828PubMed

27.

Jasienska G, Kapiszewska M, Ellison PT et al (2006) CYP17 genotypes differ in salivary 17-beta estradiol levels: a study based on hormonal profiles from entire menstrual cycles. Cancer Epidemiol Biomarkers Prev 15:2131–2135PubMedCrossRef

28.

Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH (2005) CYP17, urinary sex steroid levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 14:815–820PubMedCrossRef

29.

Daneshmand S, Weitsman SR, Navab A, Jakimiuk AJ, Magoffin DA (2002) Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17alpha-hydroxylase/C(17–20) lyase promoters. Fertil Steril 77:274–280PubMedCrossRef

30.

Loukola A, Chadha M, Penn SG et al (2004) Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur J Hum Genet 12:321–322PubMedCrossRef

31.

Skibola CF, Bracci PM, Paynter RA et al (2005) Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk. Cancer Epidemiol Biomarkers Prev 14:2391–2401PubMedCrossRef

32.

Paynter RA, Hankinson SE, Colditz GA et al (2005) CYP19 (aromatase) haplotypes and endometrial cancer risk. Int J Cancer 116:267–274PubMedCrossRef

33.

Berstein LM, Imyanitov EN, Kovalevskij AJ et al (2004) CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. Cancer Lett 207:191–196PubMedCrossRef

34.

Tao MH, Cai Q, Zhang ZF et al (2007) Polymorphisms in the CYP19A1 (Aromatase) gene and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 16:943–949PubMedCrossRef

35.

Haiman CA, Stram DO, Pike MC et al (2003) A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 12:2679–2692PubMedCrossRef

36.

Long JR, Shu XO, Cai Q et al (2007) CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women. Int J Obes (Lond) 31:418–423CrossRef

37.

Haiman CA, Dossus L, Setiawan VW et al (2007) Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 67:1893–1897PubMedCrossRef

38.

www.hapmap.org, Accessed November 16 2007

39.

Niu X, Burger S, Van loon S, Kohler B (2007) Cancer incidence and mortality in New Jersey 2000–2004. Cancer Epidemiology Services, New Jersey Department of Health and Senior Services

40.

Ries L, Kosary C, Hankey B et al (1997) SEER cancer statistics review, 1973–1994. NIH Pub. No. 97-2789, National Cancer Institute, Bethesda

41.

Parazzini F, Negri E, La Vecchia C et al (1998) Role of reproductive factors on the risk of endometrial cancer. Int J Cancer 76:784–786PubMedCrossRef

42.

Weiderpass E, Adami HO, Baron JA et al (1999) Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 10:277–284PubMedCrossRef

43.

Weiderpass E, Baron JA (2001) Cigarette smoking, alcohol consumption, and endometrial cancer risk: a population-based study in Sweden. Cancer Causes Control 12:239–247PubMedCrossRef

44.

Rebbeck TR, Troxel AB, Wang Y et al (2006) Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst 98:1311–1320PubMedCrossRef

45.

Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1727PubMedCrossRef

Title: Variants in hormone biosynthesis genes and risk of endometrial cancer
Authors: Sara H. Olson
Irene Orlow
Sharon Bayuga
Camelia Sima
Elisa V. Bandera
Katherine Pulick
Shameka Faulkner
Diana Tommasi
Daniel Egan
Pampa Roy
Homer Wilcox
Ali Asya
Ippolito Modica
Haider Asad
Robert Soslow
Ann G. Zauber
Publication date: 01-11-2008
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 9/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-008-9160-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2008

A review of the relationship between tooth loss, periodontal disease, and cancer

Systemic folate status and risk of colorectal cancer

Re: Louwman WJ et al. On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 19:97–106

Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk

Physical activity, sedentary behavior, and the risk of colon and rectal cancer in the NIH-AARP Diet and Health Study

Influence of body mass index on prognosis in gynecological malignancies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer